PSC category

Drugs and Biologicals

PSC 6505

FY2026 ended Sep 30 · data still posting · data as of 2026-11-01†

† DoD contract data posts to USAspending about 90 days after award.

$28.3B
Federal awards
FY2026 · data still posting
PSC 6505
Code

PSC code 6505 (Drugs and Biologicals) accounted for $28.3B in federal contracts in FY2026. FY2026 ended Sep 30 and its data is still posting. Computed

Obligations by year

Computed
$20B
FY20
$47.9B
FY21
$44.1B
FY22
$22.7B
FY23
$23.9B
FY24
$26.2B
FY25
$28.3B
FY26 partial
▲ 31%
FY20 to FY25

Key takeaways

Computed
FY2026 ended Sep 30 · data still posting · data as of 2026-11-01
  • Drugs and Biologicals (PSC 6505) accounted for $28.3B in federal obligations in FY2026, compared with $26.2B in FY2025.
  • It ranked #2 among product and service codes by federal dollars in FY2026 (data still posting).

Top recipients

Computed

No recipients recorded.

Top funding agencies

Computed

No agencies recorded.

Awards

Source

Largest FY2026 awards in this category

Awards coded PSC 6505 that started in FY2026, by the amount obligated on each so far.

AwardIDRecipientObligatedStartEndPlace
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 September36C24026K1012Mckesson Corporation$1.5B2026-09-012026-09-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 November36C24026K1002Mckesson Corporation$1.4B2025-11-012025-11-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 May36C24026K1008Mckesson Corporation$1.4B2026-05-012026-05-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 July36C24026K1010Mckesson Corporation$1.2B2026-07-012026-07-31Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 June36C24026K1009Mckesson Corporation$1.2B2026-06-012026-06-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 April36C24026K1007Mckesson Corporation$1.2B2026-04-012026-04-30Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 October36C24026K1001Mckesson Corporation$1.2B2025-10-012025-10-31Texas
Express Report: Pharmaceutical Prime Vendor (PPV)FY2026 March36C24026K1006Mckesson Corporation$1.2B2026-03-012026-03-31Texas

Largest awards in this category

Award of 10M Treatment Courses of Oral Protease Inhibitor PF-07321332
awarded 2021$12.5B
COVID-19 Vaccine Production
awarded 2020$11.1B
100M SARS-COV-2 MRNA-1273 Vaccine Doses
awarded 2020$8.2B
Production of Therapeutic in Support of National Emergency Response to…
awarded 2021$5.6B
COVID-19 Vaccines for International Donation
awarded 2021$4.2B
COVID-19 Adult MDV Vaccine
awarded 2022$4B
COVID-19 Oral Antiviral MK-4482 (Molnupiravir)
awarded 2021$2.2B
COVID-19 Mrna Vaccines
awarded 2022$1.8B

Total value over each award’s life, largest first.

Related

Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.